World's largest psychedelic drug trial approved by Health Canada
Apex Labs, a leader in psychedelic medicine, gains a No Objection Letter from Health Canada, meaning they can start recruiting for their latest trial.
After much fervour around exploring the benefits of psychedelic drugs further, a lab in Canada has now been granted permission from Health Canada to start the world’s largest clinical trial to date on psilocybin.
Apex Labs (Vancouver, Canada) specialises in bringing psilocybin-derived treatments to market for patients with depression and anxiety in PTSD. They will be starting a randomised, double-blind, placebo-controlled Phase IIb study – APEX-002-A01-03 – to test the safety of APEX-52 for the treatment of anxiety and depression in adults with PTSD.
APEX-52 is a microdose, orally administered synthetic psilocybin drug product. Administered as a microdose means that the patients wouldn’t experience psychedelic events. Apex labs is hoping to recruit 294 patients from across Canada. Trials have been conducted with PAE-52 before, but not to this proposed scale.
"We are incredibly proud of the team for making APEX the first-mover in take home psilocybin treatment" Tyler Powell, APEX Chief Executive Officer commented. "Our focus is to execute a rigorous clinical pathway and positive results from APEX-002-A01-03 will allow APEX to move swiftly into Phase III commercialisation studies."
The patients will self-administer the dose, with the drug carefully manufactured according to guidelines and under GMP, making it safe and easy for home use, with physician oversight and regular check ins.
The tolerability and efficacy of the drug will be measured against the global standards for anxiety, depression, PTSD and suicidality, compared to baseline.
"After treating PTSD patients in my clinic for more than 20 years, we've seen the limitations of current treatments and the promise of psilocybin but more research is required," stated Dr Mark Johnston, APEX-002-A01-03 Principal Investigator and Director of Central Nervous System Research at Centricity Research. "This trial is significant as we are studying microdose psilocybin at a scale never done before. Microdoses are not associated with an intense psychedelic effect, allowing them to be taken at home and offering an easy to access, yet potentially equally effective pathway for psilocybin. Centricity has the facilities and operational expertise to begin a trial of this complexity swiftly."
Apex will be recruiting for the trial in the first half of 2023, with the trial then taking place over a three month period.
"As a Canadian company we are excited to conduct this trial in our own backyard," commented Arron Victory, APEX Chief Strategy Officer and Canadian Armed Forces Veteran. "We have been incredibly pleased with Health Canada's efficient, thoughtful feedback and support across APEX submissions, exemptions, and approvals."
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance